Prognostic Value of Cardial Stress Perfusion Imaging

NCT04564794 | Completed

• 1 other identifier: 2020PI174
• Study Type: observational
• Target: 11,952
• Locations: 1 country
• Sites: 1

Brief Summary

Stress myocardial perfusion scintigraphy is a reference examination for the detection and monitoring of coronary patients, and this examination has already been the subject of multiple validation studies, including for the stratification of the prognosis of these patients, information that can usefully guide therapeutic choices. Today, this reduction in the activity of injected radiopharmaceuticals is taking place in a growing number of nuclear medicine departments. The implications are unknown in terms of the risk of death of the different parameters studied

Conditions

Coronary Artery Disease

Keywords

coronary; myocardial perfusion tomoscintigraphy.

Outcome Measures

Primary Outcomes (1)

• Overall mortality

  to evaluate the prognostic contribution of low radiation stress myocardial perfusion scintigraphy on overall mortality risk , overall mortality will be calculate

  6 months

Secondary Outcomes (3)

• Death from cardiac causes, either proven or suspected (death from unexplained causes),

  6 months

• Major cardiac events (death of proven or suspected cardiac cause, myocardial infarction, myocardial revascularization procedure),

  6 months

• Cardiac mortality and major cardiac events.

  6 months

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Any coronary patient suspected or proven to have had a stress myocardial perfusion tomoscintigraphy performed at the Nancy CHRU and corresponding to a standardized model of expression of results (i.e. more than 10,000 reports).

You may qualify if:

• Any coronary patient suspected or proven to have had a stress myocardial perfusion tomoscintigraphy performed at the Nancy CHRU and corresponding to a standardized model of expression of results (i.e. more than 10,000 reports).

You may not qualify if:

• None

Sponsors & Collaborators

• Central Hospital, Nancy, France: lead

Study Sites (1)

Nancy Hospital

Vandœuvre-lès-Nancy, Grand Est, 54511, France

Location

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases

Study Officials

• Pierre-Yves Marie, MD, PhD

  Nancy CHRU hospital

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical director

Study Record Dates

• First Submitted: September 21, 2020
• First Posted: September 25, 2020
• Study Start: December 1, 2022
• Primary Completion: July 1, 2023
• Study Completion: November 26, 2023
• Last Updated: November 29, 2023

Record last verified: 2023-11

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)